Jefferies Financial Group Reiterates Hold Rating for Bausch Health Companies (NYSE:BHC)

Bausch Health Companies (NYSE:BHC)‘s stock had its “hold” rating reiterated by equities researchers at Jefferies Financial Group in a research note issued on Thursday, MarketBeat Ratings reports. They currently have a $8.00 price target on the stock, down from their previous price target of $12.00. Jefferies Financial Group’s price objective indicates a potential upside of 24.13% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Finally, Royal Bank of Canada cut their target price on shares of Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Bausch Health Companies has an average rating of “Hold” and a consensus price target of $7.42.

Bausch Health Companies Stock Performance

Shares of Bausch Health Companies stock opened at $6.45 on Thursday. The firm has a fifty day moving average of $7.69 and a two-hundred day moving average of $7.45. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -13.43 and a beta of 0.68. Bausch Health Companies has a 52 week low of $3.96 and a 52 week high of $11.46.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BHC. Kendall Capital Management lifted its position in Bausch Health Companies by 43.4% in the 4th quarter. Kendall Capital Management now owns 17,995 shares of the company’s stock valued at $145,000 after acquiring an additional 5,445 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Bausch Health Companies in the 4th quarter valued at about $180,000. Aigen Investment Management LP bought a new stake in shares of Bausch Health Companies in the fourth quarter valued at about $180,000. Charles Schwab Investment Management Inc. boosted its position in shares of Bausch Health Companies by 1.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,284,036 shares of the company’s stock worth $10,375,000 after buying an additional 14,558 shares during the period. Finally, Handelsbanken Fonder AB grew its holdings in shares of Bausch Health Companies by 18.4% during the fourth quarter. Handelsbanken Fonder AB now owns 65,100 shares of the company’s stock worth $525,000 after buying an additional 10,100 shares in the last quarter. Institutional investors and hedge funds own 78.65% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.